#newsletter
3 digests · RSS
2026
- GLM-5.2 drops under MIT license as Fable 5 export control dispute deepensZ.ai released GLM-5.2, a 753-billion-parameter open-weights LLM under MIT license, which Simon Willison called the most powerful text-only open-weights model available. Separately, a White House report on the Fable 5 export control jailbreak drew pushback from cybersecurity expert Kate Moussouris, who said the restriction harms US cyber defense. OpenAI and Molecule.one published results from a near-autonomous AI chemist using GPT-5.4 that improved a challenging medicinal chemistry reaction. In pharma, nitazene overdose deaths confirmed by the CDC rose from 27 in 2020 to 409 in 2024, while the FTC and four state AGs sued WPATH over its gender-affirming care standards. Tyler Cowen flagged new research showing AI-native startups are organized differently from conventional venture-backed firms, drawing on Y Combinator data from 2020 to 2024.Jun 18, 2026
- US suspends Fable 5 access for foreign nationals as export controls hit frontier AIThe US government issued an export control directive suspending all access to Claude Fable 5 and Mythos 5 for foreign nationals, a move that rattled the AI industry and prompted Tyler Cowen to note the equilibrium was hard to solve for. Separately, Arvind Narayanan and Sayash Kappoor published a detailed argument that software engineers won't be replaced by AI, citing task fragmentation and the compounding cost of errors. The FDA approved Sanofi's teplizumab for children with stage 3 type 1 diabetes after it cleared a dispute between career staff and political appointees. Noah Smith asked whether Chinese corporate debt could zombify the economy, while Patrick Boyle examined how SpaceX humiliated Wall Street by retaining founder control across 25x more fundraising than typical startups.Jun 15, 2026
- DeepSeek tops GPT-5.5 as npm backdoors hit Claude Code and obesity drug race heats up at ADADeepSeek V4 Pro beat GPT-5.5 Pro on precision benchmarks this week, marking the latest round in the US-China model rivalry. A malware campaign hit 32 npm packages with roughly 117,000 weekly downloads, planting backdoors inside Claude Code startup settings. Pfizer's monthly obesity drug berobenatide continued to show promise in mid-stage data while Boehringer Ingelheim's survodutide disappointed on overall weight loss. Patrick Boyle examined what happens when a housing boom turns to bust, and Marc Rubinstein at Net Interest looked at the IPO readiness of SpaceX, Anthropic, and OpenAI.Jun 08, 2026